Covid Vaccine Race

A Q&A surrounding the two technologies with investigators from the Wistar Institute.

The federal agency has asked Johnson & Johnson to discard its COVID-19 vaccine made at a plant in Baltimore.

The committee members discussed their concerns about having sufficient data to make an informed decision around the risk vs. benefits for looking at potential FDA approvals for vaccines in this population group.

The extension changes the shelf life from 3 months to 4.5 months.

The company’s submission is for teens 12-17 years old and is based on data from its phase 2/3 trial studying its mRNA-1273 vaccine.

The agreement brings the total number of doses bought by the United States to 800 million.

Hesitancy is a hurdle we have been struggling with in general when it comes to vaccines, but even more so when it comes to COVID-19. Throw politicization and the nuances of EUA into this mix, and it’s not surprising we’re having to work exceedingly hard to expand vaccine uptake.

Deaths continue to plunge in Brazil as more vaccinations are administered.

A county-level study of COVID-19 vaccination rates by the US Centers for Disease Control and Prevention (CDC) reveals substantially lower rates in rural than in urban areas in the US.

Worries mount in Africa as only 2% of the population has received a vaccine.

The newest data for the real-world assessment show the mRNA vaccine provides greater immunogenicity in persons aged 12-15 years old than in young adults.

Reports of myocarditis were reported in mostly young adult males, 4 days after administration.

India pushes 300,000 COVID-19 death mark as worries of black fungus loom.

The company plans to file for Food and Drug Administration (FDA) authorization for the 12-17 year old population in early June.

The federal agency elongates the time from 5 days up to 1 month for thawed out doses of the Pfizer-BioNTech vaccine.

The European Union (EU) agrees to look at easing restrictions for travelers from outside the continent, depending on vaccine or country status.

A new CDC study demonstrates effectiveness in a population with high exposure to the virus.

The CDC Director Rochelle Walensky confirmed the Pfizer-BioNTech vaccine can be administered in children as young as 12 years of age.

Discriminately affected populations face a wall of hurdles, historic and contextual, in buying into COVID-19 vaccine benefit. What can clinicians and public health officials do to help?

The first US COVID-19 vaccine breaks ground again, as the first authorized for patients as young as 12 years old.

Malaysia begins nationwide lockdown due to third wave of the pandemic.

Investigators report the vaccine demonstrated it was safe, well-tolerated, and immunogenic in all age groups.

Novavax plans to deliver approximately 350 million doses to COVAX during the third quarter of 2021.

The vaccine will now be included in WHO’s COVAX initiative, which is providing greater and more equitable access to vaccines around the world.

Reaching a vaccination rate of 50% by July of 2021 could prevent 5.8 million cases and 215,790 hospitalizations.

The companies are seeking approval for anyone aged 16 and above.

Company plans to initiate a rolling submission for US Food and Drug Administration (FDA) Biologics License Application (BLA) this month for the vaccine.

Moderna reports data demonstrating a single 50 µg shot of its mRNA-1273 or mRNA-1273.351 booster shot increased neutralizing titers against SARS-CoV-2, as well as the South African and Brazilian variants.

New real-world research suggest the vaccine may help provide control of the pandemic virus.

Amongst HIV negative participants, the vaccine demonstrated a 51% efficaciousness against B.1.351.